-
Antu Biocarbohydrate Antigen CA15-3 Detection Kit Obtained Medical Device Registration Certificate
Time of Update: 2021-12-05
On November 23, Antu Biological released an announcement stating that the company had recently received the "Medical Device Registration Certificate" issued by the Henan Provincial Food and Drug Administration for the carbohydrate antigen CA15-3 detection kit (magnetic particle chemiluminescence method) for In vitro quantitative detection of the content of carbohydrate antigen CA15-3 in human serum .
-
The development prospects of the biopharmaceutical market are promising, and a large number of pharmaceutical companies are spending huge sums of money to deploy
Time of Update: 2021-12-05
However, in recent years, with the expiration of patents for some original research drugs and the continuous expansion of the biopharmaceutical market, many pharmaceutical companies in China have accelerated their deployment in the biopharmaceutical field .
-
To speed up the "going global" of the Chinese medicine industry, efforts must be made from three aspects at the same time
Time of Update: 2021-12-05
It is reported that Guangxi has been vigorously advancing the development of the Chinese medicine industry in recent years and has continuously accelerated the pace of "going global .
-
The development of Chinese medicine injection industry is limited, and the transformation to modernization is imminent
Time of Update: 2021-12-05
In this context, the industry predicts that as the country pays more and more attention to safety issues, the policy of restricting the clinical use of Chinese medicine injections will become tighter, and some companies’ products or certain varieties will be eliminated at an accelerated rate.
-
The Korean pharmaceutical company Rituximab accounts for 40% of the European market. What is the current status of domestic production?
Time of Update: 2021-12-05
Image source: Fosun Pharma AnnouncementAs the first rituximab biosimilar drug approved for marketing in China, Han Likang has a domestic sales of 2.
-
The IPO preparation team on the Sci-tech Innovation Board welcomes a pharmaceutical company again, and has repeatedly broken through the barriers
Time of Update: 2021-12-05
The prospectus shows that Baili Tianheng Pharmaceutical chose the fourth set of criteria for the Sci-tech Innovation Board for this IPO: the estimated market value is not less than RMB 3 billion, and the operating income in the most recent year is not less than RMB 300 million .
-
Novartis' generic drug unit Sandoz may sell for US$21.6 billion
Time of Update: 2021-12-05
According to reports, Thomas and Andreas of the Struengmann family sold the generic drug company Hexal to Novartis in 2005, and the company has also become part of Sandoz .
-
Ascent Pharmaceuticals Orebatinib Receives EU Orphan Drug Qualification Certification
Time of Update: 2021-12-05
Although the first and second generation drugs BCR-ABL TKI have significant clinical benefits for the treatment of CML, acquired drug resistance has always been the main challenge for the treatment of CML .
-
The high-prosperity domestic substitution of the pharmaceutical industry boosts the pharmaceutical machinery industry to usher in a new round of growth
Time of Update: 2021-12-05
For many companies' performance increase, the analysis believes that this is mainly due to the high prosperity of the downstream pharmaceutical market and the continuous acceleration of domestic substitution .
-
Hengrui put down his "prudence" and was forced to use two "big tricks" in a row
Time of Update: 2021-12-05
After revenue exceeds 10 billion, it can still maintain an ultra-high growth rate of about 30%, which eventually prompted Hengrui to choose What are the reasons for the capitalization of R&D investment?It is true that with the increase in Hengrui’s base, the pressure on corporate growth has doubled.
-
The cold wave has exceeded the standard by a large margin!
Time of Update: 2021-12-05
In recent years, under the influence of multiple factors such as continuous increase in policies, capital entry, and the influx of talents, China's biomedical industry has developed rapidly and accelerated the pace of innovation and upgrading.
-
This year, more than one billion yuan API projects have started construction
Time of Update: 2021-12-05
After the third phase of the project is fully completed, it is expected to achieve an annual output value of about 12 billion yuan .
-
Forecast of the seventh batch of centralized procurement of anti-tumor drugs! Who are you most looking forward to for the 10 varieties in the over 4 billion market?
Time of Update: 2021-12-05
com shows that in 2020, the terminal sales of anti-tumor drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 billion yuan, an increase of 10.
-
The resignation of directors in the pharmaceutical industry, Zhendong Pharmaceutical also joins the ranks
Time of Update: 2021-12-05
Zhendong Pharmaceutical issued an announcement on the evening of November 19, stating that the company’s board of directors recently received a written application for resignation from director and president Ma Shifeng.
-
6.5837 million yuan!
Time of Update: 2021-12-05
7 million yuan by the State Administration for Market Regulation for abusing its dominant position in the sales of Batroxobin concentrate in China; Enterprises have imposed administrative penalties for the implementation of monopoly agreements, with a total of 764 million yuan fined and confiscated .
-
The development of "orphan drugs" cannot be ignored, and Yasheng Pharmaceuticals and Junshi Biotech have achieved new breakthroughs
Time of Update: 2021-12-05
For example, in addition to Yasheng Pharmaceuticals, the author has learned that Junshi Biotech has also received new news in the field of "orphan drugs" recently, that the anti-PD-1 monoclonal antibody drug Teriprizumab independently developed by Junshi Biotech has been awarded the FDA orphan drug Qualified for the treatment of esophageal cancer (EC) .
-
Ten billion yuan in CTLA-4 antibody drug market, attracting local pharmaceutical companies to deploy
Time of Update: 2021-12-05
Hengrui Medicine announced on the evening of November 21 that it had reached a strategic cooperation and exclusive license agreement with CStone Pharmaceuticals on the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region .
-
Eli Lilly initiates first head-to-head study of CGRP migraine drug
Time of Update: 2021-12-05
Last weekend, Eli Lilly announced the initiation of a phase 4 clinical trial to compare its monthly subcutaneous CGRP migraine drug Emgality with oral tablets Nurtec ODT for the preventive treatment of paroxysmal migraine (EM) .
-
The demand for high-end pharmaceutical equipment is growing stronger, and the market share is expected to continue to increase
Time of Update: 2021-12-05
From the above data, the market share of domestic high-end pharmaceutical equipment is continuing to increase, which also means that high-end equipment companies are ushering in opportunities and are expected to accelerate the pace of import substitution in the future .
-
500 million yuan of anti-gout drugs, two pharmaceutical companies have reviewed it in one day!
Time of Update: 2021-12-05
Prior to this, domestically produced febuxostat has been approved for listing, involving companies including Zhu Yangxin, Wanbang, and Hengrui.
The manufacturers involved include Jiangsu Wanbang (40mg, 16 tablets, winning price of 16.
